Breast cancer, particularly the HER2 positive subtype, presents a formidable challenge in clinical oncology, necessitating innovative therapeutic strategies. Here, we present a novel immunoliposome-based formulation designed for targeted delivery of paclitaxel and miRNA inhibitors to HER2-positive breast cancer cells. Through a rigorous preclinical evaluation encompassing in vitro cellular studies and an in vivo tumor xenograft model, we demonstrate the formulation's remarkable efficacy in inhibiting cell proliferation, inducing apoptosis, and suppressing tumor growth. Histopathological assessments reveal a favourable safety profile with minimal adverse effects on normal tissues. Furthermore, the study unveils the synergistic interaction between paclitaxel and miRNA inhibitor within the formulation, offering a potential avenue for combination therapy. The novelty of the study lies in the development of a precise and targeted therapeutic approach tailored to HER2-positive breast cancer, addressing critical gaps in current treatment modalities. Our findings underscore this innovative formulation's clinical relevance and translational potential, paving the way for personalised and effective therapies in HER2-positive breast cancer management.

中文翻译：

---

在 HER2 阳性乳腺癌中发挥最大疗效：miR155 抑制剂和紫杉醇免疫脂质体联合递送用于靶向治疗


乳腺癌，尤其是 HER2 阳性亚型，在临床肿瘤学中提出了巨大的挑战，需要创新的治疗策略。在这里，我们提出了一种基于免疫脂质体的新型制剂，旨在将紫杉醇和 miRNA 抑制剂靶向递送至 HER2 阳性乳腺癌细胞。通过包括体外细胞研究和体内肿瘤异种移植模型在内的严格临床前评估，我们证明了该制剂在抑制细胞增殖、诱导细胞凋亡和抑制肿瘤生长方面的显着疗效。组织病理学评估显示良好的安全性，对正常组织的不利影响最小。此外，该研究揭示了紫杉醇和 miRNA 抑制剂在制剂中的协同相互作用，为联合治疗提供了一条潜在的途径。该研究的新颖性在于开发了一种针对 HER2 阳性乳腺癌的精确和靶向治疗方法，解决了当前治疗方式中的关键差距。我们的研究结果强调了这种创新制剂的临床相关性和转化潜力，为 HER2 阳性乳腺癌管理的个性化和有效疗法铺平了道路。